NASDAQ:IFRX
InflaRx N.V. Stock News
$1.18
-0.0200 (-1.67%)
At Close: May 10, 2024
InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
01:00pm, Thursday, 13'th Jun 2019
InflaRx N.V. (IFRX), an innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the treatment of the first patient in a phase
InflaRx shares plummet over 90% after drug test failure
08:18pm, Wednesday, 05'th Jun 2019
InflaRx shares plummet over 90% after the biotech company said its drug for an inflammatory skin disorder failed to show a show a significant response compared to a placebo. The drug, called IFX-1, is
InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
11:49am, Wednesday, 05'th Jun 2019
IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1.
InflaRx N.V. (IFRX) Reports Q1 Loss, Lags Revenue Estimates
01:15pm, Thursday, 23'rd May 2019
InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 30.65% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
InflaRx Reports First Quarter 2019 Financial & Operating Results
12:00pm, Thursday, 23'rd May 2019
IFX-1: New long-term efficacy data from Phase IIa clinical trial in Hidradenitis Suppurativa presented; approval granted to initiate Phase IIa trial in Canada in Pyoderma.
InflaRx (IFRX) Catches Eye: Stock Jumps 7.5%
12:45pm, Wednesday, 10'th Apr 2019
InflaRx (IFRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
